Rain Therapeutics to issue 7.4M shares in IPO at an estimated price range between $16-$18

Rain Therapeutics, a Phase 3-ready biotech developing in-licensed therapies for cancer(RAIN) to issue 7.4M shares in initial public offering at an expected price between$16-$18…
Read More